vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and STRATASYS LTD. (SSYS). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $137.0M, roughly 1.2× STRATASYS LTD.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -2.2%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -7.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Stratasys, Ltd. is an American-Israeli manufacturer of 3D printers, software, and materials for polymer additive manufacturing as well as 3D-printed parts on-demand. The company is incorporated in Israel. Engineers use Stratasys systems to model complex geometries in a wide range of polymer materials, including: ABS, polyphenylsulfone (PPSF), polycarbonate (PC), polyetherimide and Nylon 12.
ESPR vs SSYS — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $137.0M |
| Net Profit | — | $-55.6M |
| Gross Margin | — | 41.0% |
| Operating Margin | 50.6% | -16.6% |
| Net Margin | — | -40.6% |
| Revenue YoY | 143.7% | -2.2% |
| Net Profit YoY | — | -109.0% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $137.0M | ||
| Q2 25 | $82.4M | $138.1M | ||
| Q1 25 | $65.0M | $136.0M | ||
| Q4 24 | $69.1M | — | ||
| Q3 24 | $51.6M | $140.0M | ||
| Q2 24 | $73.8M | $138.0M | ||
| Q1 24 | $137.7M | $144.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $-55.6M | ||
| Q2 25 | $-12.7M | $-16.7M | ||
| Q1 25 | $-40.5M | $-13.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-26.6M | ||
| Q2 24 | $-61.9M | $-25.7M | ||
| Q1 24 | $61.0M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 41.0% | ||
| Q2 25 | — | 43.1% | ||
| Q1 25 | — | 44.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 44.8% | ||
| Q2 24 | — | 43.8% | ||
| Q1 24 | — | 44.4% |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | -16.6% | ||
| Q2 25 | 8.6% | -12.0% | ||
| Q1 25 | -34.0% | -9.1% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | -18.2% | ||
| Q2 24 | 3.5% | -18.9% | ||
| Q1 24 | 52.5% | -17.0% |
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | -40.6% | ||
| Q2 25 | -15.4% | -12.1% | ||
| Q1 25 | -62.2% | -9.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -19.0% | ||
| Q2 24 | -83.9% | -18.6% | ||
| Q1 24 | 44.3% | -18.0% |
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $-0.06 | — | ||
| Q1 25 | $-0.21 | — | ||
| Q4 24 | $-0.14 | — | ||
| Q3 24 | $-0.15 | — | ||
| Q2 24 | $-0.33 | — | ||
| Q1 24 | $0.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $71.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $852.5M |
| Total Assets | $465.9M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | $71.5M | ||
| Q2 25 | $86.1M | $71.1M | ||
| Q1 25 | $114.6M | $70.1M | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | $64.0M | ||
| Q2 24 | $189.3M | $70.9M | ||
| Q1 24 | $226.6M | $91.1M |
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $852.5M | ||
| Q2 25 | $-433.5M | $902.4M | ||
| Q1 25 | $-426.2M | $784.8M | ||
| Q4 24 | $-388.7M | — | ||
| Q3 24 | $-370.2M | $831.8M | ||
| Q2 24 | $-344.2M | $850.5M | ||
| Q1 24 | $-294.3M | $866.1M |
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $1.1B | ||
| Q2 25 | $347.1M | $1.1B | ||
| Q1 25 | $324.0M | $1.0B | ||
| Q4 24 | $343.8M | — | ||
| Q3 24 | $314.1M | $1.1B | ||
| Q2 24 | $352.3M | $1.1B | ||
| Q1 24 | $373.1M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $6.9M |
| Free Cash FlowOCF − Capex | — | $2.5M |
| FCF MarginFCF / Revenue | — | 1.8% |
| Capex IntensityCapex / Revenue | 0.0% | 3.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $6.9M | ||
| Q2 25 | $-31.4M | $-1.1M | ||
| Q1 25 | $-22.6M | $4.5M | ||
| Q4 24 | $-35.0M | — | ||
| Q3 24 | $-35.3M | $-4.5M | ||
| Q2 24 | $-7.2M | $-2.4M | ||
| Q1 24 | $53.8M | $7.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5M | ||
| Q2 25 | — | $-8.4M | ||
| Q1 25 | — | $789.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | $-6.3M | ||
| Q2 24 | $-7.3M | $-4.9M | ||
| Q1 24 | $53.8M | $5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | -6.1% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | -4.5% | ||
| Q2 24 | -9.9% | -3.6% | ||
| Q1 24 | 39.0% | 3.5% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 3.2% | ||
| Q2 25 | 0.0% | 5.3% | ||
| Q1 25 | 0.0% | 2.8% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 1.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
SSYS
Segment breakdown not available.
